Novo Nordisk has announced that it is expanding patient access to Wegovy® (semaglutide) injection 2.4 mg by enabling select telehealth providers to work directly through NovoCare® Pharmacy to offer a simplified pathway for self-paying patients seeking access to authentic, FDA-approved Wegovy®. 

CenterWell Pharmacy is the dispensing pharmacy managing prescription fulfilment and delivery for NovoCare® Pharmacy, which is now allowing direct access to Hims & Hers Health, Inc., LifeMD, and Ro.

All doses of Wegovy® are fully available. In March 2025, Novo Nordisk launched NovoCare® Pharmacy to provide direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of USD 499 per month for self-paying patients. 

Additionally, the Wegovy® savings offer was updated so that eligible self-paying patients can also get the USD 499-per-month price at their local pharmacy. Now, Novo Nordisk is working with these telehealth companies to make it as convenient as possible for their patients to get the authentic, FDA-approved Wegovy® they need at an affordable self-pay cost. 

"Wegovy® continues to be in high demand as there are 100 million Americans living with obesity. We believe patients living with this chronic disease who want and need treatment under the care of a licensed healthcare professional, including those embracing the growing telehealth community, deserve to get the real thing," said Dave Moore, Executive Vice President, US Operations and President of Novo Nordisk Inc.

"Making Wegovy® available via these telehealth channels, with its clinically-tested weight loss in its premium pen delivery device, is an important step forward in allowing patients to receive care in the way they choose and helping them to achieve their weight loss goals with an authentic, FDA-approved medicine," added Moore.

First approved in 2021, Wegovy® is the only FDA-approved semaglutide treatment for weight loss, and the medicine that changed how healthcare professionals (HCPs) treat patients with obesity as the first weekly GLP-1 for chronic weight management. Wegovy® currently supports nearly 1.5 million patients in the US. 

Adding to the mounting reasons why HCPs choose Wegovy®, the FDA expanded the label in 2024 to include an indication for reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. Wegovy® and the semaglutide molecule continue to be studied across a variety of chronic conditions.

Novo Nordisk is focused on driving change for people living with obesity and is looking for new and innovative ways to connect more patients with the authentic medicines they are seeking and deserve, like Wegovy®.